Facebook
Twitter
LinkedIn
Forward
Diagnosing and Managing EoE: Evolving Guidelines, Emerging Treatments (CME Monograph)
Target Audience
This educational activity is intended for gastroenterologists, other physicians, and physician assistants involved in the care of patients with eosinophilic esophagitis.
Learning Objectives
After completing this activity, participants will be better able to:
- Review current guidelines on the diagnosis of EoE
- Review clinical trial data on emerging treatments for EoE
- Apply the latest EoE guidelines to the management of EoE
- Integrate strategies for interdisciplinary care of patients with EoE
Faculty
 | Associate Professor of Clinical Medicine Director, Gastroenterology Physiology Laboratory Director, Advanced Esophagology Fellowship The University of Pennsylvania Perelman School of Medicine Philadelphia, Pennsylvania |
 | Professor of Medicine Division of Gastroenterology and Hepatology Adjunct Professor of Epidemiology Director, Center for Esophageal Diseases and Swallowing University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina |
 | Professor of Medicine Division of Gastroenterology & Hepatology Co-Director, Northwestern Eosinophilic Gastrointestinal Disease Program Feinberg School of Medicine Northwestern University Chicago, Illinois |
 | Associate Professor of Medicine Division of Asthma, Allergy, and Immunology University of Virginia School of Medicine Charlottesville, Virginia |
Disclosure Policy
MedEdicus LLC adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to commencement of the activity.
Faculty
Evan S. Dellon, MD, MPH, is a consultant for Abbott, AbbVie Inc, Adare Pharma Solutions, Aimmune Therapeutics, Alimentiv, Allakos Inc, Amgen Inc, Arena Pharmaceuticals, Inc, AstraZeneca, Avir Pharma, Biorasi, LLC, Bristol-Myers Squibb Company, Calypso Biotech, Calyx, Celgene Corporation, Celldex Therapeutics, Eli Lilly and Company, Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline, Gossamer Bio, Landos Biopharma, Morphic Therapeutic, Parexel International Corporation, Receptos, Regeneron Pharmaceuticals, Inc, Salix Pharmaceuticals, Sanofi, Shire, and Takeda Pharmaceuticals USA, Inc; is a contracted researcher for Adare Pharma Solutions, Allakos Inc, AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation, Ellodi Pharmaceuticals, GlaxoSmithKline, Meritage Pharma Inc, Nutricia, Receptos, Regeneron Pharmaceuticals, Inc, Shire, and Takeda Pharmaceuticals USA, Inc; and receives educational grant funding from Allakos Inc, Banner Life Sciences, and Holoclara.
Nirmala Gonsalves, MD, is a consultant for AbbVie Inc, Allakos Inc, AstraZeneca, Nutricia, Regeneron Pharmaceuticals, Inc, and Sanofi.
Kristle L. Lynch, MD, is a contracted researcher for Allakos Inc and AstraZeneca.
Emily C. McGowan, MD, PhD, is a contracted researcher for Regeneron Pharmaceuticals, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Takeda Pharmaceuticals USA, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC; Takeda Pharmaceuticals USA, Inc; Gastroenterology & Endoscopy News; or CMEZone.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 252
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation